BETHLEHEM, Pa., Aug. 8, 2011 /PRNewswire/ — Saladax Biomedical,
Inc., a privately held company developing and commercializing novel
diagnostic assays to achieve the promise of personalized medicine
for new and existing therapeutics, announced today that Kaan
Medikal will serve as the exclusive distributor of Saladax’s My5-FU
diagnostic test throughout the Turkish market.
My5-FU measures levels of 5-flourouracil (5-FU), a widely used
chemotherapy drug used in conjunction with other drugs in
first-line therapy for colorectal cancer and other solid tumors.
The assay technology enables oncologists to determine the
optimal dose of 5-FU for each individual patient, thereby
increasing the effectiveness of the drug and lessening the risk of
severe toxicity and side effects. My5-FU is the first of
Saladax’s innovative dose management tests commercially
available.
“Kaan Medikal is an ideal partner for Saladax as we continue to
expand the distribution and marketing of My5-FU in the European
Union and other significant markets,” said Adrienne Choma, Esq.,
vice president, marketing and sales of Saladax. “Interest in
Turkey for My5-FU is strong, and we expect that Kaan Medikal’s
market leadership in diagnostic testing and excellent reputation
for quality will enable significant opportunities for growth, which
will translate into improved care for patients undergoing
chemotherapy treatment for colorectal and other solid tumor
cancers.”
Fatih Ordu, general manager of Kaan Medikal, stated, “We are
delighted to be working with Saladax to market My5-FU in Turkey.
We’re confident that Saladax’s innovative diagnostic test
will allow physicians in our country to better monitor and provide
more accurate treatment to their patients.”
About Saladax Biomedical, Inc.
Saladax Biomedical develops and commercializes novel diagnostic
assays to achieve the promise of personalized medicine through dose
management and companion di
‘/>”/>
